Moerae Matrix, which is developing inhaled therapies for the treatment of idiopathic pulmonary fibrosis and other lung diseases, has announced the appointment of Bill Bradford as Chief Medical Officer. Bradford was most recently a Senior Fellow at Intermune.
Bradford commented, “I am excited to be joining Moerae at this important time in the company’s evolution as we prepare to advance our MMI-0100 clinical program into patients. MMI-0100, a selective inhibitor of MK2 that has demonstrated significant anti-inflammatory and anti-fibrotic activity in a variety of different preclinical models, has a potential role in the management of a number of major disease states that currently represent significant unmet medical needs, including idiopathic pulmonary fibrosis. I look forward to working with the talented team at Moerae to develop MMI-0100 and an impressive pipeline of compounds.”
Moerae Matrix CEO Cynthia Lander said, “As a leader and widely-respected peer in the pulmonary community based on his pioneering development work in idiopathic pulmonary fibrosis, Bill will be a valuable addition to the Moerae team as we move our platform of MAPKAP Kinase 2 inhibitors forward. Bill’s strategic capabilities and experience are unparalleled. He will strengthen our corporate and clinical development and research efforts as we advance our lead drug, MMI-0100, for pulmonary disorders and other conditions, as well as progress our earlier stage pipeline.”
In August 2014, the company announced that it had initiated a Phase 1 study of MMI-0100 for the treatment of IPF. MMI-0100 is being developed as a dry powder inhalation formulation.
Read the Moerae Matrix press release.
